Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.
This lecture was part of a CME accredited symposium: 'Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition' held at ERA-EDTA in Copenhagen, Denmark.
Professor Colin Baigent, MD is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology. He is an Honorary Consultant in Cardiovascular Epidemiology at the Oxford University Hospitals Foundation Trust.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionSGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME
Prof. Christoph Wanner
- Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibitionUnderstanding CKD and SGLT2-inhibition: What are the key mechanisms?
Prof. Per-Henrik Groop